Trinity Biotech Has Received Regulatory Approval To Conduct Initial European Pre-Pivotal Trial, The Data Will Be Utilized To Advance The Technical Optimization Of The Next Generation CGM Device Ahead Of The Pivotal Trial Planned In 2025
Portfolio Pulse from Benzinga Newsdesk
Trinity Biotech has received regulatory approval to conduct an initial European pre-pivotal trial for its next-generation CGM device. The data from this trial will be used to optimize the device ahead of a pivotal trial planned for 2025.
June 24, 2024 | 11:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Trinity Biotech has received regulatory approval to conduct an initial European pre-pivotal trial for its next-generation CGM device. This is a significant step towards the pivotal trial planned for 2025.
The regulatory approval for the pre-pivotal trial is a positive development for Trinity Biotech as it moves closer to the pivotal trial in 2025. This approval could boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100